Patents by Inventor Daniel L Flynn

Daniel L Flynn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190091217
    Abstract: The present invention relates to methods of inhibiting TIE2 kinase useful in the treatment of tumor growth, invasiveness, intravasation, dissemination, metastasis, and immunosuppression. Specifically, the invention relates to methods of using 1-(3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea and salts thereof of Formula I.
    Type: Application
    Filed: April 19, 2018
    Publication date: March 28, 2019
    Inventors: Daniel L. FLYNN, Michael D. KAUFMAN, Bryan D. SMITH, Marc RUDOLTZ
  • Publication number: 20170209428
    Abstract: The present invention relates to methods of inhibiting TIE2 kinase useful in the treatment of tumor growth, invasiveness, intravasation, dissemination, metastasis, and immunosuppression. Specifically, the invention relates to methods of using 1-(3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea and salts thereof of Formula I.
    Type: Application
    Filed: August 31, 2016
    Publication date: July 27, 2017
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Brian D. Smith, Marc Rudoltz
  • Publication number: 20170079966
    Abstract: It has been shown that Compound 1 unexpectedly and potently inhibits TIE2 kinase, and that Compound 1 inhibits drug resistance mechanisms in both the tumor and in the surrounding microenvironment through balanced inhibition of TIE2, MET, and VEGFR2 kinases. Thus, Compound 1 provides a single therapeutic agent able to address multiple hallmarks of cancer by inhibiting TIE2, MET, and VEGFR2 kinases in the tumor microenvironment [Hanahan 2011]. Through its balanced inhibitory potency vs TIE2, MET, and VEGFR2, Compound 1 provides an agent which inhibits three major tumor (re)vascularization and resistance pathways (ANG, HGF, VEGF) and blocks tumor invasion and metastasis. Compound 1 exhibits anti-tumor activity alone and in combination with other targeted agents or chemotherapy.
    Type: Application
    Filed: October 14, 2015
    Publication date: March 23, 2017
    Inventors: Daniel L. FLYNN, Michael D. KAUFMAN, Bryan D. SMITH
  • Patent number: 9457019
    Abstract: The present invention relates to methods of inhibiting TIE2 kinase useful in the treatment of tumor growth, invasiveness, intravazation, dissemination, metastasis, and immunosuppression. Specifically, the invention relates to methods of using 1-(3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea and salts thereof of Formula I.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: October 4, 2016
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Bryan D. Smith, Marc Rudoltz
  • Patent number: 9387202
    Abstract: Compounds useful in the treatment of mammalian cancers and especially human cancers according to Formula I are disclosed. Pharmaceutical compositions and methods of treatment employing the compounds disclosed herein are also disclosed.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: July 12, 2016
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Michael D. Kaufman
  • Patent number: 9382228
    Abstract: Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 5, 2016
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Timothy Malcolm Caldwell, Michael D. Kaufman, William C. Patt, Thiwanka Samarakoon, Lakshminarayana Vogeti, Karen M. Yates
  • Patent number: 9334267
    Abstract: This invention provides compounds of Formula I: (Formula I should be inserted here) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula I; and use of a compound of Formula I for treating specified cancers.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: May 10, 2016
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Lakshminarayana Vogeti, Scott Wise, Wei-Ping Lu, Bryan Smith, James R. Henry, Philip A. Hipskind, Sheng-Bin Peng
  • Publication number: 20160101090
    Abstract: It has been shown that Compound 1 unexpectedly and potently inhibits TRK kinases, including all three forms of TRK: NTRK1, NTRK2, and NTRK3. Additionally it has been shown that Compound 1 potently inhibits oncogenic mutated forms of TRK kinases, including fusion proteins. By way of exemplification, Compound 1 potently inhibits the NTRK1 oncogenic fusion protein TPM3/NTRK1 in cellular assays. Compound 1 inhibits TRK kinase mediated tumor growth in vivo in a TPM3/NTRK1 xenograft model.
    Type: Application
    Filed: October 14, 2015
    Publication date: April 14, 2016
    Inventors: Daniel L. FLYNN, Michael D. KAUFMAN, Bryan D. SMITH
  • Patent number: 9309224
    Abstract: Described are compounds of Formula 1 which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 12, 2016
    Assignee: Deciphera Pharmaceuticals, LLC.
    Inventors: Daniel L. Flynn, Timothy Malcolm Caldwell, Thiwanka Samarakoon, Lakshminarayana Vogeti, Michael D. Kaufman, William C. Patt, YuMi Ahn
  • Publication number: 20160046619
    Abstract: Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
    Type: Application
    Filed: August 3, 2015
    Publication date: February 18, 2016
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Thiwanka Samarakoon, Timothy Malcolm Caldwell, Lakshminarayana Vogeti, YuMi Ahn, William C. Patt, Karen M. Yates
  • Patent number: 9193719
    Abstract: Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 24, 2015
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Gary E. L. Brandt, Michael D. Kaufman, Hanumaiah Telikepalli, Timothy Malcolm Caldwell, Thiwanka Samarakoon
  • Patent number: 9187474
    Abstract: This invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I); and use of a compound of Formula (I) for treating specified cancers.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: November 17, 2015
    Assignees: Deciphera Pharmaceuticals, LLC, Eli Lilly and Company
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Lakshminarayana Vogeti, Scott Wise, Wei-Ping Lu, Bryan Smith, Timothy Malcolm Caldwell, William C. Patt, James R. Henry, Philip A. Hipskind, Sheng-Bin Peng
  • Publication number: 20150320759
    Abstract: The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound.
    Type: Application
    Filed: December 4, 2014
    Publication date: November 12, 2015
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Peter A. Petillo
  • Patent number: 9181223
    Abstract: Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 10, 2015
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Michael D. Kaufman, Daniel L. Flynn, YuMi Ahn, Lakshminarayana Vogeti, Timothy Malcolm Caldwell
  • Patent number: 9133183
    Abstract: Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 15, 2015
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Thiwanka Samarakoon, Timothy Malcolm Caldwell, Lakshminarayana Vogeti, YuMi Ahn, William C. Patt, Karen M. Yates
  • Publication number: 20150246033
    Abstract: The present invention relates to methods of inhibiting TIE2 kinase useful in the treatment of tumor growth, invasiveness, intravasation, dissemination, metastasis, and immunosuppression. Specifically, the invention relates to methods of using 1-(3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea and salts thereof of Formula I.
    Type: Application
    Filed: November 7, 2014
    Publication date: September 3, 2015
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Bryan D. Smith, Marc Rudoltz
  • Publication number: 20150218130
    Abstract: The disclosed compounds are useful in the treatment of mammalian cancers and especially human cancers. Compounds, pharmaceutical compositions, and methods of Formula I are disclosed: or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, stereoisomer, or tautomer thereof.
    Type: Application
    Filed: January 22, 2015
    Publication date: August 6, 2015
    Inventors: Daniel L. Flynn, Michael D. Kaufman
  • Publication number: 20150148380
    Abstract: Compounds useful in the treatment of mammalian cancers and especially human cancers according to Formula I are disclosed. Pharmaceutical compositions and methods of treatment employing the compounds disclosed herein are also disclosed.
    Type: Application
    Filed: November 20, 2014
    Publication date: May 28, 2015
    Inventors: Daniel L. FLYNN, Michael D, KAUFMAN
  • Publication number: 20150119392
    Abstract: This invention provides compounds of Formula I: (Formula I should be inserted here) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula I; and use of a compound of Formula I for treating specified cancers.
    Type: Application
    Filed: March 5, 2013
    Publication date: April 30, 2015
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Lakshminarayana Vogeti, Scott Wise, Wei-Ping Lu, Bryan Smith, James R. Henry, Philip A. Hipskind, Sheng-Bin Peng
  • Patent number: 9012635
    Abstract: Compounds useful in the treatment of mammalian cancers and especially human cancers according to Formula I are disclosed. Pharmaceutical compositions and methods of treatment employing the compounds disclosed herein are also disclosed.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 21, 2015
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Michael D. Kaufman